KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 129 filers reported holding KEROS THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $6,876,113 | +13.1% | 150,462 | +63.8% | 0.00% | 0.0% |
Q1 2024 | $6,081,000 | +624.2% | 91,858 | +334.9% | 0.00% | – |
Q4 2023 | $839,731 | +24.7% | 21,120 | 0.0% | 0.00% | – |
Q3 2023 | $673,306 | -20.7% | 21,120 | 0.0% | 0.00% | – |
Q2 2023 | $848,602 | +21.9% | 21,120 | +29.6% | 0.00% | – |
Q1 2023 | $696,010 | -11.1% | 16,300 | 0.0% | 0.00% | – |
Q4 2022 | $782,726 | +39.5% | 16,300 | +9.4% | 0.00% | – |
Q3 2022 | $561,000 | +35.5% | 14,900 | -0.7% | 0.00% | – |
Q2 2022 | $414,000 | -37.6% | 15,000 | +23.0% | 0.00% | – |
Q1 2022 | $663,000 | -7.1% | 12,200 | 0.0% | 0.00% | – |
Q4 2021 | $714,000 | +19.6% | 12,200 | -19.2% | 0.00% | – |
Q3 2021 | $597,000 | -6.9% | 15,100 | 0.0% | 0.00% | – |
Q2 2021 | $641,000 | -23.4% | 15,100 | +11.0% | 0.00% | – |
Q1 2021 | $837,000 | -18.2% | 13,600 | -6.2% | 0.00% | – |
Q4 2020 | $1,023,000 | +278.9% | 14,500 | +107.1% | 0.00% | – |
Q3 2020 | $270,000 | +17.9% | 7,000 | +14.8% | 0.00% | – |
Q2 2020 | $229,000 | – | 6,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Opaleye Management Inc. | 276,000 | $7,626,000 | 3.44% |
First Light Asset Management, LLC | 598,333 | $16,532,000 | 1.92% |
Fairmount Funds Management LLC | 272,498 | $7,529,000 | 1.72% |
Deep Track Capital, LP | 739,528 | $20,433,000 | 1.34% |
Nantahala Capital Management | 911,901 | $25,196,000 | 1.26% |
Octagon Capital Advisors LP | 152,249 | $4,207,000 | 1.12% |
CHI Advisors LLC | 103,429 | $2,858,000 | 1.09% |
Altium Capital Management LP | 88,000 | $2,431,000 | 0.97% |
Orbimed Advisors | 1,679,417 | $46,402,000 | 0.84% |
Parkman Healthcare Partners LLC | 47,788 | $1,320,000 | 0.49% |